Download App

Log in to access Online Inquiry
Company Overview More
BeiGene Co., Ltd. is a global biotechnology company. The company focuses on discovering, developing, manufacturing and commercializing drugs to improve treatment effectiveness and expand access to patients around the world. The company has discovered and developed three approved drugs, including BRUKINSA, a small molecule inhibitor of Bruton tyrosine kinase (BTK) for the treatment of various blood cancers, tislelizumab for anti-PD-1 antibody immunotherapy for a variety of solid tumors and blood cancers, and pamiparib, a selective small molecule inhibitor for poly ADP ribose polymerase 1 (PARP1) and PARP2. The company also has other clinical products, including BGB-283, BGB-3245, BGB-11417, BGB-A445, BGB-A425, BGB-15025, BGB-A333, BGB-A1217 and BGB-10188. The company has offices in about 30 countries on five continents, including the United States, China, Europe and Australia.
CEO: Leiqiang Ou
Market: Hong Kong motherboard
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Moomoo > Quotes > 06160 BeiGene, Ltd. > Detailed Quotes

06160 BeiGene, Ltd.

77.500-1.100-1.40%
Market Close 05/25 16:08 CCT
High
78.250
Open
75.900
Turnover
91.28M
Low
75.500
Pre Close
78.600
Volume
1.18M
Market Cap
103.48B
P/E(TTM)
Loss
52wk High
278.600
Shares
1.34B
P/E(Static)
Loss
52wk Low
73.800
Float Cap
94.56B
Bid/Ask %
-54.43%
Historical High
278.600
Shs Float
1.22B
Volume Ratio
1.24
Historical Low
61.050
Dividend TTM
--
Div Yield TTM
--
P/B
2.13
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.10%
Amplitude
3.50%
Avg Price
77.083
Lot Size
100
Float Cap
94.56B
Bid/Ask %
-54.43%
Historical High
278.600
Shs Float
1.22B
Volume Ratio
1.24
Historical Low
61.050
Dividend TTM
--
P/B
2.13
Dividend LFY
--
Turnover Ratio
0.10%
Amplitude
3.50%
Avg Price
77.083
Lot Size
100
Price Forecast

No Data

News

Comment